Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients

NCT ID: NCT03070912

Last Updated: 2025-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

257 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-19

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ECMO has improved the outcome of heart or respiratory failure and carcinogenic shock and are increasingly used. However bleeding complications occurring in up to 50% of patients are poorly understood and worsen the overall results. The aim is to investigate the occurence of bleeding and its frequency according to the type of ECMO either veno-arterial or veno-venous. The investigators also want to assess the relation of bleeding with von Willebrand Factor defects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Von Willebrand Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* informed consent of patient or person in charge
* patient supplied by an ECMO for cardiac or respiratory failure and referred to Lille University Hospital
* patient affiliated to "french social security"

Exclusion Criteria

* pregnant woman
* no consent
* no affiliation to
* patient affiliated to '
* preexisting bleeding disorders
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Lille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antoine RAUCH, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Lille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CH ARRAS

Arras, , France

Site Status

CH Boulogne

Boulogne-sur-Mer, , France

Site Status

CH DOUAI

Douai, , France

Site Status

CH Dunkerque

Dunkirk, , France

Site Status

Hôpital Cardiologie, CHU

Lille, , France

Site Status

Ch Tourcoing

Tourcoing, , France

Site Status

Ch Valenciennes

Valenciennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Moussa MD, Abou-Arab O, Staessens S, Jungling M, Labreuche J, Lamer A, Beyls C, Rousse N, Rauch A, Loobuyck V, Beaudeux C, Pierache A, Deblauwe D, Corseaux D, Dubernet M, Guilbart M, Thellier L, Mahjoub Y, Juthier F, Dupont H, De Meyer SF, Vincentelli A, Susen S, Robin E. Comparison of the effects of phosphorylcholin versus heparin-based surface coating on clinical and histologic outcomes during veno-arterial extracorporeal membrane oxygenation support: a propensity score weighted analysis. J Thromb Haemost. 2025 Jun;23(6):1879-1892. doi: 10.1016/j.jtha.2025.02.020. Epub 2025 Feb 26.

Reference Type BACKGROUND
PMID: 40020783 (View on PubMed)

Rauch A, Dupont A, Rosa M, Desvages M, Le Tanno C, Abdoul J, Didelot M, Ung A, Ruez R, Jeanpierre E, Daniel M, Corseaux D, Spillemaeker H, Labreuche J, Pradines B, Rousse N, Lenting PJ, Moussa MD, Vincentelli A, Bordet JC, Staels B, Vincent F, Denis CV, Van Belle E, Casari C, Susen S. Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia. Circ Res. 2023 Oct 27;133(10):826-841. doi: 10.1161/CIRCRESAHA.123.322752. Epub 2023 Oct 26.

Reference Type RESULT
PMID: 37883587 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-A00256-47

Identifier Type: OTHER

Identifier Source: secondary_id

2015_83

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.